-
Mashup Score: 1
In a single-institution study reported in JAMA Oncology, Cinciripini et al explored the impact of quitting smoking after a smoking cessation intervention in patients following a cancer diagnosis.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma - 2 day(s) ago
In a phase I study reported in The Lancet Oncology, Maruyama et al reported on the role of a novel dual inhibitor of EZH2 and EZH1, valemetostat, in patients with relapsed or refractory non-Hodgkin ly…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma https://t.co/2TBmXajmYZ #lymsm #lymphoma #hematology
-
-
Mashup Score: 0Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE - 2 day(s) ago
Josep M. Llovet, MD, PhD, presented the results of the phase III LEAP-012 trial, which evaluated the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization (TACE), during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr Josep Llovet: Hi. I am going to summarize the study, Phase III LEAP-012, that was aimed to compare lenva, pembrolizumab, and TACE, versus TACE, or
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE https://t.co/qTp59xcEno #hpbcsm #LiverCancer #oncology #ESMO24 @IcahnMountSinai
-
-
Mashup Score: 0Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer - 2 day(s) ago
In a prospective analysis reported in JAMA Network Open, Patel et al found that long-term health-related quality of life (HRQOL) was poorer among patients with prostate cancer who received postprostat…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer https://t.co/PGvVYDwYzC #pcsm #prostatecancer #oncology
-
-
Mashup Score: 1In Case You Missed It: Roundup From ESMO Congress 2024 - 2 day(s) ago
In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
In Case You Missed It: Roundup From ESMO Congress 2024 https://t.co/mXeqrdAYgb #oncology #ESMO24 #bladdercancer #gastroesophagealcancer #kidneycancer #blcsm #stcsm #kcsm
-
-
Mashup Score: 2Exploring Issues in Oncofertility - 2 day(s) ago
An expert panel discussed the importance of oncofertility in the delivery of high-quality cancer care at the FDA-ASCO Virtual Workshop: Measuring Toxicity in Reproductive Organs During Oncology Drug D…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
RT @ASCOPost: Exploring Issues in Oncofertility https://t.co/4IOj0aHTqB #oncology #fertility @US_FDA @ASCO @AnnPartridgeMD @DanaFarber @IBH…
-
-
Mashup Score: 6
In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how to choose among the various doublet immunotherapy options for unresectable hepatocellular carcinoma. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Ghassan Abou-Alfa: No doubt we’ re very grateful for the opportunity that we had at ESMO to present that data and
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma https://t.co/JTaCEzw6ht #hpbcsm #LiverCancer #oncology#immunotherapy #ESMO24 @GABOUALFA @LorenzaRimassa
-
-
Mashup Score: 3Addition of Adjuvant Epirubicin to Docetaxel/Cyclophosphamide in Early TOP2A-Normal Breast Cancer - 3 day(s) ago
In the Journal of Clinical Oncology, Jensen et al reported the final analysis of the phase III Danish DBCG07-READ trial, including 10-year outcomes of the addition of epirubicin to docetaxel/cyclophos…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Addition of Adjuvant Epirubicin to Docetaxel/Cyclophosphamide in Early TOP2A-Normal Breast Cancer https://t.co/kGztRZQ75E #bcsm #breastcancer #oncology
-
-
Mashup Score: 5Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer - 4 day(s) ago
Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Badve is Professor, Department of Pathology and Laboratory Medicine, and Vice Chair, Pathology Cancer Programs, at Emory University School of Medicine in Atlanta. Presented at the Lynn Sage Breast Cancer Symposium, hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer https://t.co/JcRrmwFcZE #bcsm #breastcancer #oncology #LSBC24 @WinshipAtEmory @lynnsage
-
-
Mashup Score: 2
Two experts in myelodysplastic syndromes (MDS) discussed the findings on the combination of venetoclax plus azacitidine in the treatment of higher-risk MDS with The ASCO Post. David A. Sallman, MD, Assistant Member in the Department of Malignant Hematol ogy, Moffit Cancer Center, Tampa, provided these thoughts: “The data are good—with a median duration of response of 16 months and a median survival of 26 months—but they are not so good that I am assured the ongoing phase III trial will be positive.” He
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
@calliecoombsmd @DavidSteensma @Dr_AmerZeidan Hoping VERONA will pan out , Sekkeres sounded skeptical..https://t.co/i7lEwqrMtM
-
Effect of Smoking Cessation Intervention on Survival After a Cancer Diagnosis https://t.co/7hLvmEtG5n #smoking #cancer